Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit?
Affiliations
- PMID: 21203362
- PMCID: PMC3013595
Item in Clipboard
Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit?
J Clin Aesthet Dermatol.
2008 Sep.
No abstract available
Similar articles
-
Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.J Cutan Med Surg. 2005 Oct;9(5):209-14. doi: 10.1007/s10227-005-0148-6. J Cutan Med Surg. 2005. PMID: 16502198 Review.
-
Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.Ophthalmic Plast Reconstr Surg. 2017 Jan/Feb;33(1):e21-e23. doi: 10.1097/IOP.0000000000000432. Ophthalmic Plast Reconstr Surg. 2017. PMID: 25853505
-
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.J Transl Med. 2007 Jan 26;5:7. doi: 10.1186/1479-5876-5-7. J Transl Med. 2007. PMID: 17257431 Free PMC article. Clinical Trial.
-
A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.J Am Acad Dermatol. 2018 Apr;78(4):710-716. doi: 10.1016/j.jaad.2017.12.042. Epub 2017 Dec 24. J Am Acad Dermatol. 2018. PMID: 29277731 Free PMC article.
-
Actinic keratosis and imiquimod: a review of novel carriers and patents.Expert Opin Drug Deliv. 2019 Feb;16(2):101-112. doi: 10.1080/17425247.2019.1560418. Epub 2018 Dec 24. Expert Opin Drug Deliv. 2019. PMID: 30582385 Review.
Cited by
-
Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States.Cancers (Basel). 2023 Aug 2;15(15):3927. doi: 10.3390/cancers15153927. Cancers (Basel). 2023. PMID: 37568743 Free PMC article. Review.
-
Ultraviolet Radiation Biological and Medical Implications.Curr Issues Mol Biol. 2024 Feb 29;46(3):1924-1942. doi: 10.3390/cimb46030126. Curr Issues Mol Biol. 2024. PMID: 38534742 Free PMC article. Review.
-
Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders.Sci Rep. 2021 Apr 22;11(1):8775. doi: 10.1038/s41598-021-88424-z. Sci Rep. 2021. PMID: 33888854 Free PMC article.
References
-
- Exton, PA: Graceway Pharmaceuticals; 2008. Aldara [package insert]
-
- Del Rosso JQ. The treatment of viral infections and nonmelanoma skin cancers. Cutis. 2007;79(4 Suppl):29–35. - PubMed
-
- Miller RI, Gerster JF, Owens MI, et al. Imiquimod applied topically: a novel immune response modifier and a new class of drug. Int J Immunopharmacol. 1999;21:1–14. - PubMed
-
- Hemmi H, Kaisho T, Takuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200. - PubMed
-
- Del Rosso JQ. The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis. 2005;76:241–248. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources